Laurent M. Humeau
Net Worth

Last updated:

What is Laurent M. Humeau net worth?

The estimated net worth of Dr. Laurent M. Humeau is at least $4,430,057 as of 15 May 2024. He owns shares worth $131,687 as insider, has earned $474,150 from insider trading and has received compensation worth at least $3,824,220 in Inovio Pharmaceuticals, Inc..

What is the salary of Laurent M. Humeau?

Dr. Laurent M. Humeau salary is $637,370 per year as Chief Scientific Officer in Inovio Pharmaceuticals, Inc..

How old is Laurent M. Humeau?

Dr. Laurent M. Humeau is 58 years old, born in 1967.

What stocks does Laurent M. Humeau currently own?

As insider, Dr. Laurent M. Humeau owns shares in one company:

Company Title Shares Price per share Total value
Inovio Pharmaceuticals, Inc. (INO) Chief Scientific Officer 68,587 $1.92 $131,687

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO logo
INO
Inovio Pharmaceuticals, Inc.
$1.92

Laurent M. Humeau insider trading

Inovio Pharmaceuticals, Inc.

Dr. Laurent M. Humeau has made 5 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 59,737 units of INO stock on 11 Mar 2021. As of 15 May 2024 he still owns at least 68,587 units of INO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit 4,771 N/A N/A
Option
Common Stock 4,771 N/A N/A
Option
Common Stock 1,878 N/A N/A
Option
Common Stock 3,856 N/A N/A
Option
Restricted Stock Unit 1,878 N/A N/A
Option
Restricted Stock Unit 3,856 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Common Stock 19,900 N/A N/A
Option
Restricted Stock Unit 19,900 N/A N/A
Option
Common Stock 22,545 N/A N/A
Option
Restricted Stock Unit 22,545 N/A N/A
Sale
Common Stock 10,317 $9.15 $94,401
Sale
Common Stock 10,318 $9.07 $93,584
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 19,900 N/A N/A
Option
Common Stock 19,900 N/A N/A
Option
Common Stock 27,566 N/A N/A
Option
Restricted Stock Unit 27,566 N/A N/A
Sale
Common Stock 19,466 N/A N/A
Sale
Common Stock 19,467 N/A N/A
Sale
Common Stock 19,467 $14.7 $286,165
Option
Common Stock 2,812 N/A N/A
Option
Restricted Stock Unit 2,812 N/A N/A
Option
Common Stock 19,900 N/A N/A
Option
Restricted Stock Unit 19,900 N/A N/A
Option
Restricted Stock Unit 27,567 N/A N/A
Option
Common Stock 27,567 N/A N/A
Purchase
Common Stock 4,500 $2.22 $9,990
Purchase
Common Stock 20,000 $2.5 $50,000
Option
Common Stock 2,812 N/A N/A
Option
Restricted Stock Unit 2,812 N/A N/A
Option
Restricted Stock Unit 2,666 $3.34 $8,904
Option
Common Stock 2,666 $3.34 $8,904

Inovio Pharmaceuticals key executives

Inovio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: